Specialty pipeline forecast as of May 2009

[chantell.reagan]

The following list represents specialty pipeline updates for April 2009 from DrugPipelineForecast.com. Please click on the product name to view update for individual products. To access DrugPipelineForecast, you must be a registered user of DrugManagementForum (click here to register)

ABthrax - BLA submitted

Actemra - positive Phase III results

Ampligen - PDUFA date extended

Byetta LAR - NDA submitted

Catena - negative Phase III results

Cimzia - FDA approved (removed from DrugPipelineForecast)

Dysport - FDA approved (removed from DrugPipelineForecast)

fampridine SR - NDA accepted with priority review; PDUFA date set

fingolimod - positive Phase III results

Mylinax - positive Phase III results

Oforta - FDA approved (removed from DrugPipelineForecast)

PCV13 - priority review granted

pirfenidone - mixed/positive Phase III results

pralatrexate - Priority review granted with PDUFA date set

Samsca - FDA approved (removed from DrugPipelineForecast)

solanezumab - phase III trials launched (new entry in DrugPipelineForecast)

Stelara - PDUFA date extended

talactoferrin - fast-track designation (new entry in DrugPipelineForecast)

trabedersen - positive Phase III results (new entry in DrugPipelineForecast)

Xarelto - Complete response letter received

For more information, or to search additional drugs, see DrugPipelineForecast.com